A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea
About this clinical trial
The main aim of the study is to check the side effects from overnight treatment with danavorexton and assess the tolerability of varying doses of danavorexton administered intravenously. Before starting treatment with danavorexton, participants will keep a sleep diary and use an under-mattress sensor for at least 7 nights to check regular sleep habits. There will be 3 Treatment Period up to 14 days apart. In each Treatment Period, participants will receive an intravenous (through the vein) infusion of either danavorexton or a placebo starting in the evening and continuing over a 10-hour period. A placebo looks exactly like danavorexton but does not have any medicine in it. Participants will take part in a follow-up phone appointment about a week after the last Treatment Period.
At a glance
What medical conditions were being studied?
What was the clinical trial testing?
Placebo, Danavorexton
How many participants were enrolled?
13
Were placebos part of the clinical trial?
Yes
When was the clinical trial conducted?
Mar 2022 - Nov 2022
How long was participation in the clinical trial?
Participants will be in the study for up to 65 days, including treatment and follow-up visits.
Key requirements
Sex
All
Age
18-75 years
Healthy volunteers?
No